Drug Database
Back to search

Poland· PL-100105925

DHC Ennogen

A dihydrocodeine product containing dihydrocodeini tartras, registered in Poland by Ennogen Healthcare (Europe) Limited. The same ATC class is registered in 9 of our 19 countries.

ATC N02AA08

Checked against URPL (Poland) on

Informational only — not a medical device.

SOURCE REGISTER · PLURPL (Poland)normalisedDHC EnnogenATCN02AA08REGISTER NO.PL-100105925PACKS LISTED4CHECKEDSeptember 27, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about dihydrocodeini tartrasAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Dihydrocodeine is registered in 9 of 19 countries.

Countries holding a registration under ATC N02AA08 (dihydrocodeine), each read from that country’s own register.

  • This record: Poland, from URPL (Poland)
  • 5 of them publish a price we can compare per daily dose
Search dihydrocodeine products by name

Dihydrocodeine · ATC N02AA08

9 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Germany
  • Ireland
  • Japan
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

URPL (Poland)
Active substance
Dihydrocodeini tartras
Manufacturer
Ennogen Healthcare (Europe) Limited
Country
Poland (PL)
ATC code
N02AA08
ATC class
Dihydrocodeine
Defined daily dose
0.15 g, O
Reimbursed
Not published by this register
Source register
URPL (Poland)
Last checked
September 27, 2026

Packs & prices · 4

1 priced
  • gtin
    05909990217069
    60 szt.
    PLN 65.39
  • gtin
    05909990217052
  • gtin
    05909990916511
  • gtin
    09120132390259

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

165 interactions on record for dihydrocodeine.

Graded by severity as the source publishes them — 16 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check dihydrocodeine against other medicinesHow interaction checks work

Dihydrocodeine · interactions on record

165 records

  • 16 severe
  • 147 moderate

Most severe, free to view

  • AlvimopanA06AH02severe
  • ChlorphenesinD01AE07severe
  • ChlorphenesinG01AX21severe
  • ProcarbazineL01XB01severe

2 more interactions with mechanism and management, from a commercially licensed source.

Sign in to check
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Dihydrocodeine in 9 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All dihydrocodeine products

Authorised across Europe · EMA

The same active substance is authorised in 15 EEA countries. Names it is sold under:

  • Austria · Codidol Retard, Dehace Retard
  • Belgium · Paracodine
  • Bulgaria · Дхц Енноген
  • Czechia · Dhc Ennogen
  • Germany · Dhc Ennogen, Dihydrocodein Aristo
  • Estonia · Dhc Ennogen
  • Spain · Paracodina, Tosidrin
  • France · Dicodin L.P.
  • United Kingdom (Northern Ireland) · Df118 Forte, Dhc Continus
  • Hungary · Dhc Continus, Hydrocodin
  • Ireland · Paracodin
  • Latvia · Dhc Ennogen
  • Malta · Tosidrin
  • Romania · Dhc Ennogen
  • Slovakia · Dhc Ennogen

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/9e8c117b-3bab-4ee0-9ab2-2dd63bf2ca4f
GET /v1/drugs/9e8c117b-3bab-4ee0-9ab2-2dd63bf2ca4f?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Tabletki o zmodyfikowanym uwalnianiu",
  "source": "urpl",
  "strength": "90 mg",
  "packaging": "05909990217052 ¦ Rp ¦ 26690\n30 tabl.\n05909990916511 ¦ Rp ¦ 47977\n56 tabl.\n05909990217069 ¦ Rp ¦ 47978\n60 tabl.\n09120132390259 ¦ Rp ¦ Skasowane ¦ 160623\n60 tabl.",
  "substance": "Dihydrocodeini tartras 90 mg",
  "common_name": "Dihydrocodeini tartras",
  "pl_product_id": "100105925",
  "pozwolenie_nr": "09165",
  "auth_procedure": "NAR",
  "authorisation_validity": "Bezterminowe"
}
API referenceMCP serverPlans

See everything about dihydrocodeine.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console